BioCryst Pharmaceuticals, Inc. (BCRX) Enters Overbought Territory - Tale of the Tape
BioCryst Pharmaceuticals, Inc. ( BCRX ) has moved higher as of late, but there could definitely be trouble on the horizon for this company. That is because BCRX is now in overbought territory with an RSI value of 84.76. Furthermore, estimates for the BioCryst Pharmaceuticals have been coming down, pushing it to a Zacks Rank #4 (Sell). This suggests that investors may better off exiting this stock before it falls back to Earth.
BIOCRYST PHARMA (BCRX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research